Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator

Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator

This study will look at what happens to the level of protection against hepatitis B (HB) disease if a 'helper' gel is applied to the skin over the injection site of a small dose of hepatitis B vaccine.

Inclusion Criteria:

• Previously vaccinated with conventional hepatitis B vaccine series 10 or more years ago
• Generally healthy
• Is and has been free of HB disease and/or is negative to core antibody
• Known to have sero-converted to positive after vaccine series (without extra doses)
• Speaks and understands English adequately
• Available for all 4 visits within the designated timelines (30 days)
• No allergies to HB vaccine or components
• No blood or blood components within previous 6 months
• Not pregnant or breastfeeding